Is ATOS or ANIX more profitable?

Anixa Biosciences' return on equity of -76.59% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Anixa Biosciences N/A -76.59% -67.80%

Is GUTS or ATOS more profitable?

Atossa Genetics' return on equity of -102.99% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Atossa Genetics N/A -102.99% -85.78%

Do analysts prefer ATOS or RLYB?

Atossa Genetics presently has a consensus target price of $20.33, indicating a potential upside of 815.92%. Given Atossa Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Atossa Genetics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATOS or RLYB more profitable?

Atossa Genetics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Rallybio -911.07% -40.53% -38.13%

Which has preferable valuation & earnings, ATOS or CTOR?

Citius Oncology is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.11 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is ATOS or CTOR more profitable?

Citius Oncology's return on equity of -102.98% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Citius Oncology N/A -102.98% -43.49%

Atossa Genetics (ATOS) Competitors

$2.22 -0.18 (-7.50%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.28 +0.06 (+2.93%)

As of 09/18/2026 07:30 PM Eastern

Compare

ATOS vs. ANIX, GUTS, ATRA, RLYB, and CTOR

Should you buy Atossa Genetics stock or one of its competitors? Atossa Genetics's main competitors and comparable companies include Anixa Biosciences (ANIX), Fractyl Health (GUTS), Atara Biotherapeutics (ATRA), Rallybio (RLYB), and Citius Oncology (CTOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atossa Genetics compare to Anixa Biosciences?

Atossa Genetics (NASDAQ:ATOS) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Anixa Biosciences' return on equity of -76.59% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Anixa Biosciences	N/A	-76.59%	-67.80%

Atossa Genetics has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

Anixa Biosciences has higher revenue and earnings than Atossa Genetics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Anixa Biosciences	$210K	458.50	-$10.93M	-$0.32	N/A

Atossa Genetics currently has a consensus price target of $20.33, suggesting a potential upside of 815.92%. Anixa Biosciences has a consensus price target of $10.00, suggesting a potential upside of 261.01%. Given Atossa Genetics' higher possible upside, equities research analysts plainly believe Atossa Genetics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Anixa Biosciences had 6 more articles in the media than Atossa Genetics. MarketBeat recorded 6 mentions for Anixa Biosciences and 0 mentions for Atossa Genetics. Anixa Biosciences' average media sentiment score of 0.61 beat Atossa Genetics' score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Atossa Genetics	Neutral
Anixa Biosciences	Positive

Summary

Anixa Biosciences beats Atossa Genetics on 10 of the 13 factors compared between the two stocks.

How does Atossa Genetics compare to Fractyl Health?

Fractyl Health (NASDAQ:GUTS) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Atossa Genetics' return on equity of -102.99% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Atossa Genetics	N/A	-102.99%	-85.78%

Fractyl Health currently has a consensus price target of $5.50, suggesting a potential upside of 816.67%. Atossa Genetics has a consensus price target of $20.33, suggesting a potential upside of 815.92%. Given Fractyl Health's stronger consensus rating and higher possible upside, equities analysts plainly believe Fractyl Health is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Fractyl Health has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

In the previous week, Fractyl Health had 19 more articles in the media than Atossa Genetics. MarketBeat recorded 19 mentions for Fractyl Health and 0 mentions for Atossa Genetics. Fractyl Health's average media sentiment score of 0.03 beat Atossa Genetics' score of 0.00 indicating that Fractyl Health is being referred to more favorably in the media.

Company	Overall Sentiment
Fractyl Health	Neutral
Atossa Genetics	Neutral

Atossa Genetics has lower revenue, but higher earnings than Fractyl Health. Atossa Genetics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,061.20	-$140.95M	-$0.88	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

12.7% of Atossa Genetics shares are held by institutional investors. 8.4% of Fractyl Health shares are held by insiders. Comparatively, 9.8% of Atossa Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Fractyl Health beats Atossa Genetics on 9 of the 13 factors compared between the two stocks.

How does Atossa Genetics compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Atossa Genetics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of -79.12% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Atossa Genetics	N/A	-102.99%	-85.78%

Atara Biotherapeutics has higher revenue and earnings than Atossa Genetics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.81	$32.69M	-$1.18	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

Atara Biotherapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Atara Biotherapeutics presently has a consensus price target of $9.50, suggesting a potential downside of 1.96%. Atossa Genetics has a consensus price target of $20.33, suggesting a potential upside of 815.92%. Given Atossa Genetics' higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 9.8% of Atossa Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Atara Biotherapeutics' average media sentiment score of 0.71 beat Atossa Genetics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
Atossa Genetics	Neutral

Summary

Atara Biotherapeutics beats Atossa Genetics on 10 of the 15 factors compared between the two stocks.

How does Atossa Genetics compare to Rallybio?

Atossa Genetics (NASDAQ:ATOS) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Atossa Genetics has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.85, suggesting that its share price is 185% less volatile than the broader market.

Atossa Genetics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Rallybio	-911.07%	-40.53%	-38.13%

Rallybio has higher revenue and earnings than Atossa Genetics. Rallybio is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Rallybio	$860K	106.14	-$8.98M	-$4.34	N/A

Atossa Genetics presently has a consensus target price of $20.33, indicating a potential upside of 815.92%. Given Atossa Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Atossa Genetics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Rallybio's average media sentiment score of 1.73 beat Atossa Genetics' score of 0.00 indicating that Rallybio is being referred to more favorably in the news media.

Company	Overall Sentiment
Atossa Genetics	Neutral
Rallybio	Very Positive

Summary

Atossa Genetics and Rallybio tied by winning 7 of the 14 factors compared between the two stocks.

How does Atossa Genetics compare to Citius Oncology?

Atossa Genetics (NASDAQ:ATOS) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Citius Oncology's return on equity of -102.98% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Citius Oncology	N/A	-102.98%	-43.49%

Atossa Genetics presently has a consensus target price of $20.33, suggesting a potential upside of 815.92%. Citius Oncology has a consensus target price of $6.00, suggesting a potential upside of 426.32%. Given Atossa Genetics' higher probable upside, analysts plainly believe Atossa Genetics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Citius Oncology is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Atossa Genetics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market.

In the previous week, Atossa Genetics' average media sentiment score of 0.00 equaled Citius Oncology'saverage media sentiment score.

Company	Overall Sentiment
Atossa Genetics	Neutral
Citius Oncology	Neutral

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 9.8% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Citius Oncology beats Atossa Genetics on 8 of the 11 factors compared between the two stocks.

Get Atossa Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATOS vs. The Competition

Export

Metric	Atossa Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.15M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-0.71	14.23	274.93	25.38
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	0.49	15.45	10.46	6.33
Net Income	-$34.77M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-11.55%	-1.21%	0.59%	1.12%
1 Month Performance	-15.91%	-4.42%	-2.01%	-2.67%
1 Year Performance	-82.56%	37.81%	18.09%	6.01%

Atossa Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATOS Atossa Genetics	1.9403 of 5 stars	$2.22 -7.5%	$20.33 +815.9%	-83.2%	$22.15M	N/A	N/A	14
ANIX Anixa Biosciences	3.7012 of 5 stars	$2.68 -4.3%	$10.00 +273.1%	-17.8%	$93.17M	N/A	N/A	5	Positive News Analyst Upgrade
GUTS Fractyl Health	3.1385 of 5 stars	$0.58 -5.3%	$5.50 +849.9%	-39.3%	$92.17M	$90K	N/A	102
ATRA Atara Biotherapeutics	1.8629 of 5 stars	$9.08 -1.8%	$9.50 +4.6%	-19.7%	$91.16M	$120.77M	N/A	330
RLYB Rallybio	0.5749 of 5 stars	$16.85 +2.0%	N/A	+258.6%	$89.46M	$646K	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATOS) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atossa Genetics (ATOS) Competitors

ATOS vs. ANIX, GUTS, ATRA, RLYB, and CTOR

How does Atossa Genetics compare to Anixa Biosciences?

Summary

How does Atossa Genetics compare to Fractyl Health?

Summary

How does Atossa Genetics compare to Atara Biotherapeutics?

Summary

How does Atossa Genetics compare to Rallybio?

Summary

How does Atossa Genetics compare to Citius Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atossa Genetics (ATOS) Competitors

ATOS vs. ANIX, GUTS, ATRA, RLYB, and CTOR

How does Atossa Genetics compare to Anixa Biosciences?

Is ATOS or ANIX more profitable?

Which has more volatility & risk, ATOS or ANIX?

Which has preferable valuation & earnings, ATOS or ANIX?

Do analysts rate ATOS or ANIX?

Do insiders and institutionals believe in ATOS or ANIX?

Does the media refer more to ATOS or ANIX?

Summary

How does Atossa Genetics compare to Fractyl Health?

Is GUTS or ATOS more profitable?

Do analysts recommend GUTS or ATOS?

Which has more volatility & risk, GUTS or ATOS?

Does the media favor GUTS or ATOS?

Which has better valuation and earnings, GUTS or ATOS?

Do insiders & institutionals hold more shares of GUTS or ATOS?

Summary

How does Atossa Genetics compare to Atara Biotherapeutics?

Is ATRA or ATOS more profitable?

Which has higher valuation and earnings, ATRA or ATOS?

Which has more risk and volatility, ATRA or ATOS?

Do analysts rate ATRA or ATOS?

Do institutionals & insiders have more ownership in ATRA or ATOS?

Does the media prefer ATRA or ATOS?

Summary

How does Atossa Genetics compare to Rallybio?

Do institutionals and insiders believe in ATOS or RLYB?

Which has more risk and volatility, ATOS or RLYB?

Is ATOS or RLYB more profitable?

Which has better valuation & earnings, ATOS or RLYB?

Do analysts prefer ATOS or RLYB?

Does the media favor ATOS or RLYB?

Summary

How does Atossa Genetics compare to Citius Oncology?

Is ATOS or CTOR more profitable?

Do analysts prefer ATOS or CTOR?

Which has preferable valuation & earnings, ATOS or CTOR?

Which has more risk & volatility, ATOS or CTOR?

Does the media refer more to ATOS or CTOR?

Do institutionals & insiders hold more shares of ATOS or CTOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools